In combination therapy, the triad of MET, the insulin sensitizer pioglitazone, and the GLP-1 receptor agonist exenatide has achieved positive outcomes in reducing the incidence of liver fibrosis and steatosis (Lavynenko et al., 2022). This evidence concerns the gene GLP1R and Hepatic fibrosis.